Eliem says ear­li­er drug ex­po­sure is­sues have been re­solved, drops one epilep­sy in­di­ca­tion

Af­ter be­ing forced to de­lay two Phase IIa tri­als and blam­ing CMC is­sues on a Phase Ib miss, Eliem Ther­a­peu­tics be­lieves it’s now in the clear.

The Seat­tle and UK-based biotech put out word Wednes­day morn­ing about how it con­duct­ed new ear­ly-stage stud­ies to con­firm why low ex­po­sure is­sues arose dur­ing the Phase Ib. Af­ter re­searchers com­pared the re­sults of the stud­ies, Eliem found “no mean­ing­ful dif­fer­ence” be­tween them and ruled out CMC as the rea­son for the foiled Phase Ib study, the com­pa­ny said in a press re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER